Rutinib1.5%

Myelofibrosis: Rutinib 1.5% is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults. Polycythemia Vera: Rutinib 1.5% is indicated for treatment ... Read moreMyelofibrosis: Rutinib 1.5% is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults. Polycythemia Vera: Rutinib 1.5% is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.Acute Graft-Versus-Host Disease: Rutinib 1.5% is indicated for treatment of steroid-refractory acute graft-versus host disease (GVHD) in adult and pediatric patients 12 years and older.

Pyrrolopyrimidines

Rutinib 1.5% is a selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2 (IC 50 values of 3.3 nM and 2.8 nM for JAK1 and JAK2 enzymes, respectively). These mediate the signalling of a number of cytokines and growth factors that are important for haematopoiesis and immune function.MF and PV are myeloproliferative neoplasms known to be associated with dysregulated JAK1 and JAK2 signalling. The basis for the dysregulation is believed to include high levels of circulating cytokines that activate the JAK-STAT pathway, gain-of-function mutations such as JAK2V617F, and silencing of negative regulatory mechanisms. MF patients exhibit dysregulated JAK signalling regardless of JAK2V617F mutation status. Activating mutations in JAK2 (V617F or exon 12) are found in >95% of PV patients.Rutinib 1.5% inhibits JAK-STAT signalling and cell proliferation of cytokine-dependent cellular models of haematological malignancies, as well as of Ba/F3 cells rendered cytokine-independent by expressing the JAK2V617F mutated protein, with IC 50 ranging from 80-320 nM.

Myclofibrosis: The recommended starting dose of Rutinib 1.5% is based on platelet count. A complete blood count (CBC) and platelet count must be performed before initiating therapy, every 2 to 4 weeks until doses are stabilized, and then as clinically indicated. Doses may be titrated based on safety and efficacy. Platelet count greater than 200 X 10 9 /L: Starting dose 20 mg orally twice daily. Platelet count 100 X 10 9 /L to 200 X 10 9 /L: Starting dose 15 mg orally twice daily. Platelet count 50 X 10 9 /L to less than 100 X 10 9 /L: Starting dose 5 mg orally twice daily. Polycythemia Vera: The recommended starting dose of Rutinib 1.5% is 10 mg twice daily. Doses may be titrated based on safety and efficacy. Consider decreasing the dose to 5 mg twice daily if the hemoglobin count 8 to less than 12g/dL and the platelet count 50 to less than 75 X 10 9 L.Acute Graft-Versus-Host Disease: The recommended dose of Rutinib 1.5% is 5 mg twice daily. Consider increasing the dose to 10 mg twice daily after at least 3 days of treatment if the ANC and platelet counts are not decreased by 50% or more relative to the first day of dosing with Rutinib 1.5%. Or as directed by the registered physician.

Rutinib 1.5% is to be taken orally, with or without food. If a dose is missed, the patient should not take an additional dose, but should take the next usual prescribed dose.

Fluconazole: Concomitant administration of Rutinib 1.5% with fluconazole greater than 200 mg daily may increase Rutinib 1.5% exposure due to inhibition of both the CYP3A4 and CYP2C9 metabolic pathways. Increased exposure may increase the risk of exposure-related adverse reactions. Avoid the concomitant use of Rutinib 1.5% with fluconazole doses of greater than 200 mg daily except in patients with acute GVHD.Strong CYP3A4 Inhibitors: Concomitant administration of Rutinib 1.5% with strong CYP3A4 inhibitors increases Rutinib 1.5% exposure. Increased exposure may increase the risk of exposure-related adverse reactions. Consider dose reduction when administering Rutinib 1.5% with strong CYP3A4 inhibitors. In patients with acute GVHD, reduce Rutinib 1.5% dose as recommended only when coadministered with ketoconazole, and monitor blood counts more frequently for toxicity and adjust the dose if necessary when coadministered with itraconazole.Strong CYP3A4 Inducers: Concomitant administration of Rutinib 1.5% with strong CYP3A4 inducers may decrease Rutinib 1.5% exposure. No dose adjustment is recommended; however, monitor patients frequently and adjust the Rutinib 1.5% dose based on safety and efficacy.

It is contraindicated in patients with a history of hypersensitivity to Rutinib 1.5% or any other components of this product.

The most common side effects are- Thrombocytopenia, Anemia and Neutropenia Risk of Infection, bruising, dizziness, headache Symptom Exacerbation Following Interruption or Discontinuation of treatment with Rutinib 1.5% Non-Melanoma Skin Cancer

Contraindicated in pregnancy & lactation. There are no data from the use of Rutinib 1.5% in pregnant women. Animal studies have shown that Rutinib 1.5% is embryotoxic and foetotoxic. Rutinib 1.5% must not be used during breast-feeding and breast-feeding should therefore be discontinued when treatment is started. It is unknown whether Rutinib 1.5% and/or its metabolites are excreted in human milk. A risk to the breast-fed child cannot be excluded. Available pharmacodynamic/toxicological data in animals have shown excretion of Rutinib 1.5% and its metabolites in milk Fertility: There are no human data on the effect of Rutinib 1.5% on fertility. In animal studies, no effect on fertility was observed.

Thrombocytopenia, Anemia And Neutropenia: Treatment with Rutinib 1.5% can cause thrombocytopenia, anemia and neutropenia. Manage thrombocytopenia by reducing the dose or temporarily interrupting Rutinib 1.5%. Platelet transfusions may be necessary.Patients developing anemia may require blood transfusions and/or dose modifications of Rutinib 1.5%.Severe neutropenia (ANC less than 0.5 X 109/L) was generally reversible by withholding Rutinib 1.5% until recovery.Perform a pre-treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated.Risk of Infection: Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting therapy with Rutinib 1.5% until active serious infections have resolved. Observe patients receiving Rutinib 1.5% for signs and symptoms of infection and manage promptly.Tuberculosis: Tuberculosis infection has been reported in patients receiving Rutinib 1.5%. Observe patients receiving Rutinib 1.5% for signs and symptoms of active tuberculosis and manage promptly. Prior to initiating Rutinib 1.5%, patients should be evaluated for tuberculosis risk factors, and those at higher risk should be tested for latent infection. Risk factors include, but are not limited to, prior residence in or travel to countries with a high prevalence of tuberculosis, close contact with a person with active tuberculosis, and a history of active or latent tuberculosis where an adequate course of treatment cannot be confirmed. For patients with evidence of active or latent tuberculosis, consult a physician with expertise in the treatment of tuberculosis before starting Rutinib 1.5%. The decision to continue Rutinib 1.5% during treatment of active tuberculosis should be based on the overall risk-benefit determination.Progressive Multifocal Leukoencephalopathy: Progressive multifocal leukoencephalopathy (PML) has occurred with Rutinib 1.5% treatment. If PML is suspected, stop Rutinib 1.5% and evaluate.Herpes Zoster: Advise patients about early signs and symptoms of herpes zoster and to seek treatment as early as possible if suspected.Hepatitis B: Hepatitis B viral load (HBV-DNA titer) increases, with or without associated elevations in alanine aminotransferase and aspartate aminotransferase, have been reported in patients with chronic HBV infections taking Rutinib 1.5%. The effect of Rutinib 1.5% on viral replication in patients with chronic HBV infection is unknown. Patients with chronic HBV infection should be treated and monitored according to clinical guidelines.Symptom Exacerbation Following Interruption or Discontinuation Of Treatment With Rutinib 1.5%: Following discontinuation of Rutinib 1.5%, symptoms from myeloproliferative neoplasms may return to pretreatment levels over a period of approximately one week. Some patients with MF have experienced one or more of the following adverse events after discontinuing Rutinib 1.5%: fever, respiratory distress, hypotension, DIC, or multi organ failure. If one or more of these occur after discontinuation of, or while tapering the dose of Rutinib 1.5%, evaluate for and treat any intercurrent illness and consider restarting or increasing the dose of Rutinib 1.5%. Instruct patients not to interrupt or discontinue Rutinib 1.5% therapy without consulting their physician. When discontinuing or interrupting therapy with Rutinib 1.5% for reasons other than thrombocytopenia or neutropenia, consider tapering the dose of Rutinib 1.5% gradually rather than discontinuing abruptly.Non-Melanoma Skin Cancer: Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred in patients treated with Rutinib 1.5%. Perform periodic skin examinations.Lipid Elevations: Treatment with Rutinib 1.5% has been associated with increases in lipid parameters including total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined in patients treated with Rutinib 1.5%. Assess lipid parameters approximately 8-12 weeks following initiation of Rutinib 1.5% therapy. Monitor and treat according to clinical guidelines for the management of hyperlipidemia.

There is no known antidote for overdoses with Rutinib 1.5%. Single doses up to 200 mg have been given with acceptable acute tolerability. Higher than recommended repeat doses are associated with increased myelosuppression including leukopenia, anemia and thrombocytopenia. Appropriate supportive treatment should be given. Hemodialysis is not expected to enhance the elimination of Rutinib 1.5%.

Store below 30°C in a dry place, away from sunlight. Keep out of reach of children.

Renal impairment: No specific dose adjustment is needed in patients with mild or moderate renal impairment.Hepatic impairment: In patients with any hepatic impairment the recommended starting dose based on platelet count should be reduced by approximately 50% to be administered twice daily.Elderly patients (≥65 years): No additional dose adjustments are recommended for elderly patients.Paediatric population: The safety and efficacy of Rutinib 1.5% in children and adolescents aged up to 18 years have not been established. No data are available

Pyrrolopyrimidines

Rutinib 1.5%, a kinase inhibitor, inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent localization of STATs to the nucleus leading to modulation of gene expression. Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) known to be associated with dysregulated JAK1 and JAK2 signaling. Oral administration of Rutinib 1.5% prevented splenomegaly, preferentially decreased JAK2V617F mutant cells in the spleen and decreased circulating inflammatory cytokines (eg, TNF-α, IL-6).Absorption: Rutinib 1.5% is rapidly absorbed after oral Rutinib 1.5% administration with maximal plasma concentration (Cmax) achieved within 1 to 2 hours post-dose. Oral absorption of Rutinib 1.5% was estimated to be at least 95%. Distribution: The mean volume of distribution of Rutinib 1.5% at steady-state is 72 L in patient with MF and PV in myelofibrosis patients.Half-life: the mean half-life of Rutinib 1.5% & metabolites is approximately 5.8 hours. Elimination half-life: The mean elimination half-life of Rutinib 1.5% is approximately 3 hours AUC: Mean Rutinib 1.5% Cmax and total exposure (AUC) increased proportionally over a single dose range of 5 to 200 mg.The plasma protein binding: 97%, mostly to albumin. Metabolism: Rutinib 1.5% is metabolized by CYP3A4 and to a lesser extent by CYP2C9.Excretion: Following a single oral dose of radio labeled Rutinib 1.5% in healthy adult subjects, elimination was predominately through metabolism with 74% of radioactivity excreted in urine and 22% excretion via feces. Unchanged drug accounted for less than 1% of the excreted total radioactivity.

There are no adequate and well-controlled studies in pregnant women. It is not known whether Rutinib 1.5% is excreted in human milk. Because many drugs are excreted in human milk, breastfeeding should be discontinued during treatment with Rutinib 1.5% and for two weeks after the final dose.

Use in children: The safety and effectiveness of Rutinib 1.5% in pediatric patients have not been established.